Curative Biotechnology Announces U.S. Patent Allowance Strengthening Core Ophthalmology Platform
Summary
USPTO Allows Claims Covering Topical Metformin Eye-Drop Therapy for Retinal Degeneration, Including Age-Related Macular Degeneration
Why It Matters
This announcement reflects ongoing developments in the technology sector that may impact enterprise IT strategy, consumer technology adoption, or industry competitive dynamics.
Note
This summary is generated using AI analysis of the original press release. Always refer to the original source for complete details.